Residual dyslipidemia according to low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010

Libby, 2005, The forgotten majority: unfinished business in cardiovascular risk reduction, J Am Coll Cardiol, 46, 1225, 10.1016/j.jacc.2005.07.006 Wong, 2013, Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010), Am J Cardiol, 112, 373, 10.1016/j.amjcard.2013.03.041 Raal, 2013, Prevalence of dyslipidemia in statin-treated patients in South Africa: results of the DYSlipideaemia International Study (DYSIS), Cardiovasc J Afr, 24, 330, 10.5830/CVJA-2013-071 Zhao, 2014, DYSIS-China Study Investigators. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS), Atherosclerosis, 235, 463, 10.1016/j.atherosclerosis.2014.05.916 Goodman, 2010, DYSIS Canadian Investigators. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS), Can J Cardiol, 26, e330, 10.1016/S0828-282X(10)70454-2 Querton, 2012, Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels, J Clin Lipidol, 6, 434, 10.1016/j.jacl.2012.04.002 Sirimarco, 2014, Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients, Stroke, 45, 1429, 10.1161/STROKEAHA.113.004229 Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 Koopman, 2005, Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000, Ann Fam Med, 3, 60, 10.1370/afm.214 Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 D'Agostino, 2008, General cardiovascular risk profile for use in primary care: the Framingham Heart Study, Circulation, 117, 743, 10.1161/CIRCULATIONAHA.107.699579 NHANES 2009–2010 Laboratory/Medical Technologists Procedures Manual Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention. 2009. 2001, JAMA, 285, 2486, 10.1001/jama.285.19.2486 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Ballantyne, 2008, J Am Coll Cardiol, 52, 626, 10.1016/j.jacc.2008.04.052 Mora, 2012, On-treatment non-HDL cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: the JUPITER trial, J Am Coll Cardiol, 59, 1521, 10.1016/j.jacc.2011.12.035 Javed, 2011, Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participate in Get With the Guidelines (GWTG), Am Heart J, 161, 418, 10.1016/j.ahj.2010.12.014 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Jacobson, 2014, National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary, J Clin Lipidol, 8, 473, 10.1016/j.jacl.2014.07.007 Catapano, 2011, ESC/EAS Guidelines for the management of dyslipidemia. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028 Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol, 29, 151, 10.1016/j.cjca.2012.11.032 2014, An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia- full report, J Clin Lipodol, 8, 29, 10.1016/j.jacl.2013.12.005 Jellinger, 2012, American Association of Clinical Endocrinologists'Guidelines for management of dyslipidemia and prevention of atherosclerosis, Endo Prac, 18, 1, 10.4158/EP.18.S1.1 Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 51, 1512, 10.1016/j.jacc.2008.02.034 Sirtori, 2012, Clinical response to statins: mechanism(s) of variable activity and adverse effects, Ann Med, 44, 419, 10.3109/07853890.2011.582135 Stein, 2005, Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B, Am J Cardiol, 96, 36K, 10.1016/j.amjcard.2005.08.006 Sniderman, 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk, Circ Cardiovasc Qual Outcomes, 4, 337, 10.1161/CIRCOUTCOMES.110.959247 Cromwell, 2007, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management, J Clin Lipidol, 1, 583, 10.1016/j.jacl.2007.10.001 Otvos, 2011, Clinical implications of discordance between low-density lipoprotein cholesterol and particle number, J Clin Lipidol, 5, 105, 10.1016/j.jacl.2011.02.001 Toth, 2014, Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets, Atherosclerosis, 235, 585, 10.1016/j.atherosclerosis.2014.05.914